SAN DIEGO, Sept. 14, 2015 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced the appointment of David P.
Meininger, PhD, MBA, to the newly created position of Senior
Vice President of Business Development, effective today. In this
role, Dr. Meininger will be responsible for developing new business
and strategic partnerships as well as potential licensing
opportunities. He will also manage all corporate development
activities for the Company's therapeutic products.
"I'm thrilled to welcome David to the OncoSec team. David brings
more than 20 years of experience in basic and applied scientific
research, and has led growth-oriented teams at prominent biotech
and pharmaceutical companies, including Merck. He also brings
complimentary experience to OncoSec's business development focus in
the field of immuno-oncology," said Punit
Dhillon, CEO and President of OncoSec. "His extensive
business experience and industry-acumen will provide immense value
to OncoSec as we continue to expand our drug discovery and
development activities."
Most recently, Dr. Meininger served as Executive Director,
Business Development and Licensing at Merck & Co., Inc., where
he was the global lead for biologics technologies and was
responsible for West Coast in-licensing opportunities in
immuno-oncology and other therapy areas. Prior to his Business
Development role at Merck, Dr. Meininger served as Executive
Director, Molecular Discovery. In this position, he led a team
focused on discovery, initial production, characterization, and
validation of large-molecule leads for programs across seven
Disease Area Franchises in addition to championing multiple
biologics discovery initiatives, including several supporting
KEYTRUDA® (pembrolizumab).
Prior to joining Merck, Dr. Meininger was Vice President,
Biotherapeutics at Boehringer Ingelheim GmbH. While at Boehringer
Ingelheim GmbH, he led the New Biological Entity Discovery Unit
focusing on the discovery, design, and early development of New
Biological Entities. He was also Principal Scientist, Department of
Protein Science at Amgen Inc. where his team supported multiple
Amgen Oncology and Inflammation Therapeutic Area projects.
Dr. Meininger earned a bachelor's degree in chemistry from the
University of Florida and a PhD in
biochemistry from the University of
California, San Diego. He also earned a MBA in technology
management from the University of
Washington.
About OncoSec Medical Incorporated
OncoSec is a biopharmaceutical company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is
designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety
profile and evidence of anti-tumor activity in the treatment of
various skin cancers as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse™
IL-12, is currently in Phase II development for several
indications, including metastatic melanoma, squamous cell carcinoma
of the head and neck (HNSCC), and triple-negative breast cancer
(TNBC). In addition to ImmunoPulse™ IL-12, the company is also
identifying and developing new immune-targeting agents for use with
the ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-appoints-david-p-meininger-phd-mba-as-senior-vice-president-of-business-development-300141862.html
SOURCE OncoSec Medical Incorporated